Bioactive Recombinant Immune Checkpoint Protein Dimers

Conigen’s recombinant immune checkpoint proteins, including CD28, CD80, CTLA-4, PD-1, and TIGIT mimic native dimerization to support accurate receptor-ligand interactions and immune signaling studies.

These immune checkpoint receptors are transmembrane proteins that maintain immune homeostasis by balancing activation and inhibition. Dimerization stabilizes ligand interactions and is critical for inhibitory signaling—suppressing autoimmunity and promoting peripheral tolerance. Tumors often exploit these pathways to evade immune surveillance. Mimicking native dimer structures enables mechanistic studies, antibody screening, and development of immunotherapies targeting pathways like PD-1, CTLA-4, and TIGIT.

Conigen’s protein dimers mimic native inhibitory motifs and enable analysis of co-receptor signaling, and the immune checkpoint blockade strategies. Validated in functional binding assays, these reagents are ideal for drug discovery and mechanistic research.